SummerStreet Research Partners analyst Carol Werther downgraded AMAG Pharmaceuticals Inc. (Nasdaq: AMAG) citing possible severe allergic reactions in kidney disease patients to the company's iron replacement drug Feraheme. The stock price plummeted $7.13 to close at $38.12.
